Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16, Oct 02, 2023.Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty Pharma ...Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ...SALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...RXRX POWR Grades. RXRX scores best on the Growth dimension, with a Growth rank ahead of 20.42% of US stocks. ... (NASDAQ:RXRX), sold 18,000 shares of the company on November 15, 2023. Yahoo | November 18, 2023. Insider Sell: CFO Michael Secora Offloads 50,000 Shares of Recursion Pharmaceuticals Inc (RXRX)SALT LAKE CITY, Aug. 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that it ...7 Eyl 2023 ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Tags.Feb 28, 2023 · Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.38 per share a year ago. RXRX U.S.: Nasdaq Recursion Pharmaceuticals Inc. Watch list Set a price target alert After Hours Last Updated: Dec 1, 2023 7:09 p.m. EST Delayed quote $ 7.44 0.05 0.68% After …Sep 15, 2023 · NASDAQ: RXRX Recursion Pharmaceuticals. Market Cap. $2B. Today's Change (7.88%) $0.54 ... (RXRX 7.88%) and CRISPR Therapeutics, (CRSP 2.88%) two of the most followed biotechs this year. Both ... 2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company …Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2021. Skip to main content. Skip to main menu; Skip to user menu; Login |30 Haz 2021 ... ... (Nasdaq: ABCL), Recursion Pharmaceuticals (Nasdaq: RXRX), Zymergen (Nasdaq: ZY), Desktop Metal (NYSE: DM) and Lucira Health (Nasdaq: LHDX).That’s as shares of Recursion Pharmaceuticals RXRX are exploding higher on the day. In fact, RXRX stock is currently up about 17% so far in the session. Butterfly with parabolic D leg action. This looks like classic D leg stuff. All parabolic action, few pullbacks and getting a lot of public attention.Dec 4, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. Check out our RXRX stock analysis, current RXRX quote, charts, and historical prices for Recursion Pharmaceuticals Inc Cl A stock. ... (NASDAQ:RXRX) From Seeking Alpha Oct 19, 2023 Royalty ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Benzinga. Apr. 25, 2021, 10:33 PM. Cathie Wood-led Ark Investment Management on Friday snapped up another 221,167 shares of the cryptocurrency exchange Coinbase Global Inc (NASDAQ:COIN) worth ...Price. %Change. RXRX. 6.11. Trade stocks. You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform. Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a ... The average trading volume for RXRX on November 13, 2023 was 3.54M shares. RXRX) stock’s latest price update. Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone rise by 0.37 in comparison to its previous close of 5.46, however, the company has experienced a -0.90% decrease in its stock price over the last five trading days.On October 11, 2023, Michael Secora, the Chief Financial Officer (CFO) of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 50,000 shares of the company.Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. Now trading above that level — and up in five of the last six ...20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...SALT LAKE CITY, June 20, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the initiation ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Jul 12, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia.But, since that month’s peak, RXRX’s stock ...Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart. Buy RXRX stock at Webull.Nov 30, 2023 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated Phase 2/3 POPLAR-NF2 trial of REC-2282 for progressive neurofibromatosis type 2-mutated meningiomas, tumors that form on the membrane that ...3 min read. ·. Jun 7, 2022. 2. Today we’re announcing the raise of two new Obvious funds, which combine to $461M of new capital: 4 We’ve completed the fundraise for our fourth flagship early ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.That's what's happening with Recursion Pharmaceuticals ( RXRX 1.18%), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ... Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ...... NASDAQ. Market Closed. RECURSION PHARMACEUTICALS INC (RXRX). 6.86 0.08 (1.18%) +0.08 (+1.18%) 0.08 (1.18%). As of 24 November 2023 02:00 PM EST. Currency USD.Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ...Recursion Pharmaceuticals (NASDAQ:RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio biotechnology company. It is focused on utilizing advanced technologies in biology, chemistry, automation, and computer science to discover and design therapeutics. Latest Recursion Pharmaceuticals Inc (RXRX:NSQ) share price with interactive charts, historical prices, comparative ...View real-time RXRX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ... 13 Tem 2023 ... The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation;” and so on. But rather more ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer.Nov 24, 2023 · See the latest Recursion Pharmaceuticals Inc Class A stock price (RXRX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Cathie Wood-led Ark Investment Management on Tuesday snapped up another 236,348 shares of cryptocurrency exchange Coinbase Global Inc (NASDAQ: COIN).. Coinbase has been in a free-fall mode since ...Find the latest quotes for Vanguard S&P 500 ETF (VOO) as well as ETF details, charts and news at Nasdaq.com.Jul 6, 2023 · Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares. SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Find the latest analyst research for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. ... Based on analysts offering 12 month price targets for RXRX in the last 3 months.According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of …Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. 2,015.20 +2.80(+0.14%) Advertisement Recursion Pharmaceuticals, Inc. (RXRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 6.53 -0.33 (-4.81%) At close: 04:00PM EST 6.65...Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock. Since then ...Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded. As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.View live Recursion Pharmaceuticals, Inc. chart to track its stock's price action. Find market predictions, RXRX financials and market news.Dec 4, 2023 · Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information. Sporting 7.88% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 12/01/23 when the RXRX stock price touched $7.39 or saw a rise of 5.26%. 18 Tem 2023 ... Fintel reports that on July 18, 2023, Needham reiterated coverage of Recursion Pharmaceuticals Inc - (NASDAQ:RXRX) with a Buy ...Jul 12, 2023 · Well, Nvidia (NASDAQ:NVDA) just invested $50 million to “boost Recursion’s drug-discovery companies.” Prior to today’s announcement, RXRX stock sat in negative territory for the year. SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...To find the current corn price per bushel, there are a number of websites and places to look for predictions about the commodities market. Corn prices are listed on sites like NASDAQ and AgWeb if you want a quick answer.SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business ...That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ...Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares surged 73.9% to close at $31.30 on Friday after the company priced its IPO at $18 per share.Pre-Market Quotes Nasdaq-100 Ownership Search News + Insights Solutions Recursion Pharmaceuticals, Inc. Class A Common Stock P/E & PEG Ratios …Over the past 3 months, 6 analysts have published their opinion on Recursion Pharmaceuticals (NASDAQ:RXRX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...12 Tem 2023 ... SALT LAKE CITY, TORONTO and MONTRÉAL, July 12, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company ...Recursion Pharma (NASDAQ: RXRX) made waves this week.On Wednesday, the firm reported a hefty $50 million cash infusion from Nvidia to support efforts in developing AI models that speed up drug ...Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day. Now trading above that level — and up in five of the last six ...Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia.But, since that month’s peak, RXRX’s stock ...Stock Exchange NASDAQ Ticker Symbol RXRX Full Company Profile Financial Performance In 2022, RXRX's revenue was $39.84 million, an increase of …Shares of Recursion Pharmaceuticals (RXRX 4.89%) were skyrocketing 82% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence.The US$14.13 analyst price target for RXRX is 3.5% less than our estimate of fair value Does the July share price for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX ) reflect what it's really worth?9 Kas 2023 ... ... (NASDAQ: RXRX), a leading clinical stage techbio company decoding biology to industrialize drug discovery. The two companies are working ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has gone decline by -0.34 in comparison to its previous close of 7.39, however, the company has experienced a 12.79% increase in its stock price over the last five trading days. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer.Overview News Recursion Pharmaceuticals Inc. No significant news for in the past two years. Key Stock Data N/A EPS (TTM) $-1.47 $1.48 B ) Shares Sold Short 35.50 M Change from Last 7.40% Percent...Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. 524%. S&P Return. 133%. Rule Breakers. ... (RXRX 1.18%), an innovative biotech. The company's shares ...2023-09-11 09:35:31 ET. Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug development, it could soon mark itself as the leading competitor in a space that will probably prove to be quite lucrative.15 Kas 2023 ... Graphic designer/iStock via Getty Images. AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday ...Nasdaq rxrx, templeton growth fund, penny stocks to buy tomorrow
IRVINE, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that on December …. Nasdaq rxrx
stock uvxySALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations ...Nov 27, 2023 · Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This will be used […] Jul 12, 2023 · Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ... Nov 22, 2023 · That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target ... Webull offers RXRX Ent Holdg (RXRX) historical stock prices, in-depth market analysis, NASDAQ: RXRX real-time stock quote data, in-depth charts, free RXRX options chain data, and a fully built financial calendar to help you invest smart. Buy RXRX stock at Webull.AI-driven drug discovery firm Recursion Pharmaceuticals (NASDAQ:RXRX) added ~17% on Wednesday after ARK Innovation ETF (NYSEARCA:ARKK), managed by famous stock picker Cathie Wood, bought ~3.8M of ...Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. Average portfolio weight of all funds dedicated to RXRX is 0.48%, a decrease of 14.38%. Total shares owned by institutions decreased in the last three months by 7.71% to 130,292K shares.JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023.According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of …Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.SALT LAKE CITY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.Find the latest historical data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.SALT LAKE CITY, Dec. 6, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery ...The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $10.00 expecting RXRX to rise to ...NASDAQ. ` No trades. Upcoming Earnings. EPS. Market Cap. Div Yield ... NASDAQ:RXRX Price Today By TradingView. Add to Watchlist · Overview · Value · TrendOn October 11, 2023, Michael Secora, the Chief Financial Officer (CFO) of Recursion Pharmaceuticals Inc (NASDAQ:RXRX), sold 50,000 shares of the company.RECURSION PHARMACEUTICALS, INC. RXRX on Nasdaq.Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ...RXRX Recursion Pharmaceuticals Inc Bayer and Recursion Focus Research Collaboration on Oncology. Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.12 Tem 2023 ... buy RXRX Stock? or time to buy Nvidia Stock Price? A portion of this ... The Stock Market Will Finally Move (TOMORROW!) StockedUp New 6.4K ...SALT LAKE CITY, July 12, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry ...24. Walkme Ltd (NASDAQ:WKME) SaaS company WalkMe is one of the stocks with negative beta. The company in August posted second quarter results. Adjusted EPS in the quarter came in at $0.00 beating ...Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Recursion Pharmaceuticals (NASDAQ: RXRX) hit headlines hard earlier in the year as artificial intelligence giant Nvidia announced a $50 million direct investment in the biotech stock.Recursion Pharmaceuticals (NASDAQ:RXRX) has witnessed quite a roller-coaster year. A resounding investment of $50 million from tech titan Nvidia (NASDAQ:NVDA) in July rocketed its shares.May 29, 2023 · On May 8, Recursion Pharmaceuticals (RXRX 7.88%) announced that it was going to buy a pair of AI-enabled drug discovery biotechs, Cyclica and Valence, for a total of $87.5 million -- paid in stock. Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …Jan 12, 2022 · So should Recursion Pharmaceuticals (NASDAQ:RXRX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of ... Average portfolio weight of all funds dedicated to RXRX is 0.77%, an increase of 46.27%. Total shares owned by institutions increased in the last three months by 18.96% to 141,638K shares.NASDAQ:RXRX. Stock Report. RXRX. Recursion Pharmaceuticals. Stock Analysis. Analyst Forecasts. ... RXRX Stock 12 Months Forecast. Average Price Target. $16.60 (124.63 ...Find the latest on short interest for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Find the latest dividend history for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.According to Recursion Pharmaceuticals Inc [NASDAQ:RXRX], the company’s sales were 11.02 billion in the recent quarter, which represents an 43.56% jump. Gross Margin for this corporation currently stands at -22.11% with Operating Margin at -616.74%, Pretax Margin comes in at -601.05%, and Net Margin reading is -601.05%.Nov 30, 2023 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today celebrated the opening of its ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has ...November 16, 2023 at 10:06 PM · 4 min read. In a notable insider transaction, CFO Michael Secora of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) sold 50,000 shares of the company's stock on ...20 Eyl 2022 ... (NASDAQ:RXRX). The stock is now deep in Busted IPO territory. Do the shares merit that fate or is something better ahead? An analysis ...Chief Business Officer (Nasdaq: RXRX). Recursion University of Cambridge. St Petersburg, Florida, United States. 3K followers 500+ connections. See your mutual ...RXRX Recursion Pharmaceuticals Inc Bayer and Recursion Focus Research Collaboration on Oncology. Berlin, Germany and Salt Lake City, USA, Nov. 09, 2023 (GLOBE NEWSWIRE) ...Find the latest Insider Activity data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.3 min read. ·. Jun 7, 2022. 2. Today we’re announcing the raise of two new Obvious funds, which combine to $461M of new capital: 4 We’ve completed the fundraise for our fourth flagship early ...Recursion Pharmaceuticals Inc (NASDAQ:RXRX) 7.06 Delayed Data As of Nov 17 +0.39 / +5.85% Today’s Change 4.54 Today ||| 52-Week Range 16.75 -8.43% Year-to-Date …Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built ...When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Recursion (NASDAQ: RXRX) is a clinical-stage biotechnology company. It develops drugs for a variety of diseases, including Alzheimer's, cancer, and rare diseases. The company was founded in 2013 and is based in Salt Lake City, Utah.When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Find the latest Institutional Holdings data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com. At the time, Nvidia (NASDAQ:NVDA) had just investing $50 million in the company to help it create new AI models, and software to create new drug candidates. Since then, RXRX dropped to about $6 a ...Yet, risky stocks can also often offer attractive upside potential. Let's look at two examples: Recursion Pharmaceuticals ( RXRX 4.40%) and Madrigal Pharmaceuticals ( MDGL 1.83%). These two ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Fiscal Q3 2023 ended 9/30/23. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed... Real time Recursion Pharmaceuticals (RXRX) stock price quote, stock graph, news & analysis.Welcome to Recursion: The Future of TechBio. Decoding Biology To Radically Improve Lives. Explore Our Story: We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. It’s complex biology, decoded.Fintel reports that on May 9, 2023, Needham reiterated coverage of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a Buy recommendation.. Analyst Price Forecast Suggests 206.61% Upside. As of ...NASDAQ. ` No trades. Upcoming Earnings. EPS. Market Cap. Div Yield ... NASDAQ:RXRX Price Today By TradingView. Add to Watchlist · Overview · Value · TrendRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past year finance.yahoo.com - August 24 at 9:26 AM: Connor Clark & Lunn Investment Management Ltd. Buys 83,879 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) marketbeat.com - August 22 at 5:37 AMAfter announcing that it would get a $50 million investment from NVIDIA ( NVDA 0.45%) on July 12, Recursion Pharmaceuticals ( RXRX 10.49%) saw its stock blast off, rising 87% over the following ...Find the latest Financials data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.Recursion Pharmaceuticals has a market capitalisation of US$1.9b and burnt through US$113m last year, which is 6.0% of the company's market value. Given that is a rather small percentage, it would ...Recursion Pharmaceuticals Inc (NASDAQ: RXRX)’s stock price has increased by 1.33 compared to its previous closing price of 6.78. However, the company has seen a 3.00% increase in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-26 that Nvidia will help Recursion build a massive supercomputer. This …SALT LAKE CITY , Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference: Jefferies London Healthcare Conference – November 14-16, Oct 02, 2023.Benzinga. Apr. 25, 2021, 10:33 PM. Cathie Wood-led Ark Investment Management on Friday snapped up another 221,167 shares of the cryptocurrency exchange Coinbase Global Inc (NASDAQ:COIN) worth ...RXRX Is Still Unprofitable. As a clinical stage biotech company, Recursion's financials are somewhat predictably steeped in red ink. The company has yet to report a profit - and even at that, its ...Cathie Wood can't get enough of Recursion Pharmaceuticals (RXRX 7.88%) stock. Through her Ark Innovation ETF, the maverick growth stock portfolio manager bought shares of the biotech three times ...SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations .... Brite co insurance reviews, can alcohol cause afib